Panel Session: Planning Your Exit Strategy
Eva-Lotta Allan has more than 30 years of experience in the healthcare industry. During this time, she has been a senior executive and Board member at both public and private companies. Most recently, Eva-Lotta was Chief Business Officer (and previously a Board Member) at Immunocore, where she held full responsibility for all aspects of business development and played an instrumental role in the $320 million fundraising in 2015. Prior to this, Eva-Lotta served as Chief Business Officer and member of the Executive Committee and Euronext IPO team for Ablynx NV, acquired in 2018 by Sanofi for EUR 3.9 billion.
Eva-Lotta also held senior positions at Vertex Pharmaceuticals (Europe) Ltd, Oxford Asymmetry International plc (now Evotec), Oxford Glycosciences (now part of UCB Celltech) and Amersham International (now part of GE Healthcare).
Eva-Lotta Allan currently serves as Non-Executive Director and Member of the Corporate Governance Committee and the R&D Sub-Committee of the Oslo listed company, Targovax ASA and is a Non-Executive Director of Crescendo Biologics and Chairman of AIM-listed C4X Discovery. Eva-Lotta was also a Board Member of the UK BioIndustry Association (BIA).
In her 29 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Kate co-leads biotech investments and activities and her investments include small-molecule, biotherapeutic and gene therapy drug discovery and development projects as well as drug discovery platforms in a broad range of clinical areas.
Kate played an active role in setting up the Dementia Discovery Fund (DDF), an SV managed fund, and serves on the DDF Investment Committee.
Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.
Outside of SV, Kate won the Lifetime Achievement Award, presented by the BioIndustry Association UK in January 2017. She also serves on the Board of the Francis Crick Institute. At weekends Kate spends time in Wales where she rides horses and mountain bikes, grows vegetables and competes in bog snorkelling competitions.
In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine on a six month engagement stepping down as Chair in December 2020. On December 8th 2020 the UK started COVID-19 vaccinations - the first Western country to do so.
Jens has more than 15 years of venture capital experience in biopharma and 10 years of operational experience in drug discovery and development as well as company creation. He has invested over 500 million USD and was involved in 18 IPOs like CRISPER, TP Therapeutics or Principia and 12 M&A transactions. He was also involved in building the first modern anti aging biotech Sirtris. Jens is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare IT companies. Before joining Apollo Ventures, Jens served as President of SR One for eight years. He is also co-founder and Managing Director of Action Potential Venture Capital (APVC). Previously, Jens was a General Partner at TVM Capital leading early-stage investments in Boston and was CEO and President of SelectX Pharmaceuticals. Before his investment career, Jens was leading research teams and pharma collaborations at Enanta Pharmaceuticals (NASDAQ: ENTA) and Mitotix.
William Enright has been Vaccitech’s Chief Executive Officer and a member of its board of directors since August 2019. From June 2008 to November 2018, Mr. Enright served as the Chief Executive, President and Director of Altimmune, Inc., a biopharmaceutical company. Prior to joining Altimmune, Inc., Mr. Enright held various positions at GenVec, Inc., leaving as Head of Business Development. Mr. Enright holds a MA and BS in Biology from SUNY at Buffalo and a MS in Business Management from Johns Hopkins University.
Tim is Chairman and Managing Partner at Abingworth LLP, a leading global life sciences venture investment firm. Tim joined Abingworth in 2005 having been Chief Executive of Abingworth’s portfolio company, Astex Therapeutics, and was instrumental in establishing it as one of the leading UK biotechnology companies. Tim has held a number of senior management positions in the US and Europe, including CEO of both Datascope Corp. and Thackray Inc, and General Manager at Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD. He is a former Director of the BIA and sat on the BVCA Venture Committee and the Wellcome Trust / NHS Health Innovation Challenge Fund. During his time at Abingworth Tim has taken board roles in a number of companies including Adaptate Biotherapeutics, Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, and Sientra.
Before joining Samsara as CSO, Peter spent 15 years at Sanofi, most recently as Global Head of External Innovation, Drug Discovery. Prior to this role he led global drug discovery departments across Germany, France, and the US, and has contributed to the advancement of many projects into clinical development across multiple therapeutic areas. He started his career at AstraZeneca after postdoctoral studies at the University of Pennsylvania, a PhD from Cambridge University, and a BSc in Chemistry from Imperial College London. He holds an MBA from the University of Bath. Over his career in big pharma, he has published numerous papers and patents and was co-editor of the textbook Small Molecule Medicinal Chemistry: Strategies and Technologies (Wiley).
At Shift Bioscience I'm developing therapeutics for mitochondrial and nuclear rejuvenation. At U. Cambridge and the Crick Institute, I identified small molecules that eliminate mitochondrial DNA mutations, which cause rare mitochondrial disease and are sufficient to accelerate ageing phenotypes in mouse models. Shift Bioscience was founded to commercialize novel anti-ageing molecules targeting mitochondria and uncover new rejuvenation biology through novel bulk and single-cell clock methodologies.
Peter is Chief Executive Officer of Grey Wolf, having co-founded the Company in 2017. He has over 16 years of experience in biomedical research leading drug discovery projects in immuno-oncology, rare genetic diseases and neurodegeneration. Prior to founding Grey Wolf, he led target ID and discovery projects at Vertex Pharmaceuticals. Peter holds a PhD in Biochemistry and Molecular Genetics from the University of Bristol and a BSc in Biochemistry.
Dr Melanie Lee, PhD, CBE, is CEO of LifeArc. Melanie has pursued a 30-year career in healthcare R&D and gained leadership experience both from the biopharmaceutical industry and from the medical research charity sector. Melanie’s previous roles have included Chief Scientific Officer at BTG PLC (most recently) as well as senior positions at GSK, Celltech and UCB. She has previously held Trustee appointments at Cancer Research Technology and Cancer Research UK and currently serves on the Board of Directors of Sanofi UK DRI Ltd.
Trained in the lab of a Nobel laureate in biochemistry in the U.S., Dr Ogrunc complemented her training in top European research institutes: ETH-Zurich, Pasteur Paris, IFOM Milan and INSERM. She is an expert in cancer biology and aging.
She co-founded StarkLabs with Dr Thierry Mathieu
Dr Heather Fairhead is the founder and CEO of Phico Therapeutics, which she set up with seed funding from Cambridge Research and Innovation Limited (CRIL). Heather has a wide range of research experience, encompassing molecular biology, microbiology and biochemistry, gained at the Universities of Nottingham, Sheffield and Cambridge where she is also a regular guest lecturer.
She spent a year in the laboratory of Dr Peter Setlow at the University of Connecticut, US working on the proteins that comprise the core of Phico's antibacterial therapy. Heather has a 1st Class Hons degree in Biotechnology, a PhD in Molecular Microbiology and is a Fellow of the Royal Society of Medicine. Prior to starting her scientific career, Heather gained several years experience working in marketing/sales and business administration for a range of companies including Roneo Vickers, Burberry's and latterly Cambridge Consultants.
Heather featured in the Daily Mail's Top 100 Women of Achievement in 2004, and won the CEN Business Woman of the Year award in 2005, having been runner-up in 2004. Heather is a regular lecturer at the University of Cambridge and Imperial College.
James is CEO and Founder of LabGenius - a venture-backed deep tech company using machine learning to discover new protein therapeutics.
James completed his EPSRC-funded PhD at Imperial College London where he developed a platform for targeted drug delivery using re-engineered protein nanocages. Prior to his PhD, James completed a BSc in Biology with Microbiology and an MRes in Systems and Synthetic Biology, at Imperial College London. In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact. In 2018, James was featured on Forbes' 30 Under 30 list for Science & Healthcare. James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).
Emma is a thought leader and Chief Executive of Weatherden with a distinguished track record in leadership, strategy, ideation and company creation from across the life sciences, consulting and venture capital industries. She began her career at KPMG in the life sciences team before moving into technical advisory, followed by three years at SV Health Investors working on biotech company creation in immunology and oncology. She is an Advisor and sits on the Investment Committee of Science Creates Ventures, a new EIS fund focused on deep tech investments, and her advocacy for the biotech industry includes advising multiple companies in stealth and serving on biotech industry committees.
John brings to OBN extensive leadership and managerial competence developed within well respected Blue-Chip, Governmental and SME organisations, specialised in the Life Sciences Sectors. Over his 34 years working in this space (including 20 years at CEO level), he has developed considerable experience and expertise within the Biotech, pharmaceutical and medical technology arenas ranging through research, technical & commercial development, registration, manufacture, marketing, and sales.
Immediately prior to joining OBN he was Managing Partner of LifeAgility Associates, a specialist consultancy focused on strategy and business support for Life Sciences SME's and also provided expert participation in the development of the UKTI Government Life-Sciences 10-year strategy plan.
Previous appointments include Managing Director of IPS Specials (a cGMP, MHRA licensed manufacturer of pharmaceuticals), Managing Director of Key Organics Ltd (a leading manufacturer of chemical intermediates), Managing Director of Synerga Ltd (a start-up drug discovery venture), Chairman & CEO of TraceTag International Ltd (a biotech company specialising in hi-tech diagnostics), Managing Director of AgriSense-BCS (specialist biorationals manufacturer), and senior management roles in Zeneca, Novo Nordisk (Denmark), Monsanto (Belgium), and Shell.
John received the HSBC / SVBA Business Leader of the Year 2019 Award.
He holds a BSc (Hons) in Biology from the University of Salford, a PhD in Biochemistry from the University of Southampton and an MBA from the University of Surrey.
Karen is an immunologist by training with 30 years’ experience in drug discovery in a range of therapeutic areas including oncology, inflammatory diseases, and neurology. She has broad experience in small molecule and antibody drug discovery, as well as in cell and gene therapy. At Adaptimmune, Karen is the SVP of Pipeline Research, leading the teams developing novel engineered cell therapies for the treatment of cancer. Karen joined Adaptimmune from GSK where she was Vice President, Head of the Immunology Innovation Fund with responsibility for sourcing and evaluating internal and external project opportunities in immunology, across multiple therapeutic areas including oncology. Prior to this, she led GSK’s Cytokine, Chemokine and Complement Discovery Performance Unit taking projects from target Identification and validation through to late-stage clinical trials. Earlier in her career, she held roles as Head of Biology for UCB Pharma, Vertex and British Biotech. Karen started her research career at Imperial College in London, carrying out research on signal transduction mechanisms using cell, biochemical and imaging techniques.
Geert-Jan, Managing Partner, has a leading role in the Investment Team and the Portfolio as an experienced life sciences investor who led the firm’s successful investments and served on the boards (sometimes also in an executive capacity) of portfolio companies bluebird bio, (IPO on Nasdaq 2013), Acorda (IPO on Nasdaq 2006), PanGenetics (sold to Abbott in 2009), Transave (reverse-merger into Insmed in 2010), Exosome Diagnostics (sold to Bio-Techne), Promedior (sold to Roche in 2020) and KaNDy Therapeutics (sold to Bayer in 2020). Geert-Jan serves on the Board of several Forbion portfolio companies and in addition to his portfolio management activities, Geert-Jan closely works with management teams of various Forbion portfolio companies on clinical development strategies and regulatory matters, such as IND/ NDA filings, Special Protocol Approval (SPA), and US / EU Orphan designations for several products reflected by being a co-author of several Forbion and Forbion portfolio related scientific publications.
Before co-founding Forbion, Geert-Jan was an Investment Director at ABN AMRO Capital Life Sciences since 2001. Before that, at Byk Gulden (now Takeda) he served as a Clinical Research Manager, where his group was responsible for design and execution of early and late stage clinical trials forming the basis for two global product registrations: Daxas® and Alvesco® in fields of COPD and asthma. For both products he was a member of the Global Medical Marketing group. Before Byk, Geert-Jan was Medical Adviser at Searle (now Pfizer) in the field of Arthritis & Pain, being involved in the clinical development of Celebrex® and its European Advocate Development.
Geert-Jan received his Medical Degree from the University of Utrecht (NL), spent two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht
Ian has over 25 years of international experience in management and transactions within the life sciences sector. In addition to his role at F2G, he is currently an Operating Partner of London-based Advent Life Sciences LLP. Ian previously spent eight years as CEO of the privately held oncology R&D company, Chroma Therapeutics Limited. Prior to that he was Senior Vice President, Business Development at UK biotechnology company Celltech Group plc. Ian has worked extensively in licensing, M&A and market development in the UK, Europe and the US and holds a BSc (Hons.) from University College London and an MBA from Boston University. He holds Board positions at Clinigen Group plc and is Chairman of Bioventix plc.
Formerly Head of Medical Device & Diagnostics Business Solutions and Cardiovascular Therapeutic Area Head at Covance, one of the world’s premier clinical research organizations. MBA from London Business School. Honorary Cardiology Consultant at Oxford University Hospitals.
Mark Stevenson has been Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific since August 2017 and has responsibility for the company’s life sciences, analytical instruments, laboratory products and specialty diagnostics businesses as well as the company’s innovation and digital strategy. He joined the company as Executive Vice President and President, Life Sciences Solutions, through the acquisition of Life Technologies in 2014.
Mark previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation in 2008.
Mark received his MBA from Henley Management School in the U.K. and his bachelor’s degree in chemistry from the University of Reading, also in the U.K. He serves on the board of the Personalized Medicine Coalition.
Over the last 30+ years, Neil’s career has seen him progress more than 10 drugs to patients and lead a number of drug discovery projects in areas of cardiovascular, neurology, inflammation and oncology. For 15 years, Neil was Senior Vice President of Biology at Astex Pharmaceuticals, helping the company establish itself at the forefront of drug discovery by leading the biology and pre-clinical teams to deliver two new cancer drugs (Kisqali; ribociclib and Balversa; erdafitinib in partnership with Novartis and Janssen respectively) to market. Before that, he was Director of the Immunology Platform at GlaxoSmithKline (GSK). Neil is also Deputy Chair of the UK MRC DPFS panel and Chair of the MRC CLD/ADI committee. He has authored more than 40 publications and patents and sits on the advisory boards of several scientific institutions in the UK. He received his doctorate in Biochemistry from King’s College London.
James is an Intellectual Property Litigation partner in Venner Shipley’s legal services team. He has extensive experience in commercial litigation, intellectual property and alternative dispute resolution (ADR). His practice has covered a wide variety of matters including; commercial litigation, admiralty, employment, insolvency, banking, pensions, and mortgage claims. He focuses on intellectual property disputes; and has been involved in cases such as the Supreme Court decision in R. v. Prudential on the issue of whether legal professional privilege applies to non-lawyers representing the interests of the IP community, the House of Lords decision in RPR v Yeda concerning patent entitlement to a cancer therapy, CCH v the Law Society of Upper Canada a decision of the Canadian Supreme Court concerning copyright in judgments, trade mark cases such as the Enterprise Court decision protecting the Dyno-Rod mark from rogue plumbers, as well as design and confidential information disputes in the High Court.
James’ work also extends to anti bribery compliance, data protection matters; compliance for politicians and political campaigns, advertising and promotions, as well as issues with data capture for those dealing in virtual currency and customer data. He has been an ad hoc advisor to various UK MPs and MEPs on a range of IP and dispute issues. Through his engagement with policy makers he has extensive Government relations experience and advises clients on how to prepare for legislative changes and regulation compliance. As a consequence of his regulatory work with politicians James also has a sub-specialism in election law.
Tim’s career in the life sciences has encompassed start ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including NM Rothschild, Hambrecht and Quist, UBS, SG Cowen and Pacific Growth Equities. In 2013 he founded Longcross Advisers, a life science-focused corporate finance firm. He gained his PhD from the MRC’s Laboratory of Molecular Biology in Cambridge and a BSc (Hons) in biochemistry from Imperial College, London.
As Chief Technical Officer of Ultromics, Gary Woodward manages the company’s technical strategy to ensure rapid and flexible product exploitation in an increasingly dynamic marketplace.
Before being named CTO, Gary was Ultromics’ Head of Research and Development responsible for all global RnD activities, including end-to-end management of technology development, transfer and IP.
Gary maintains an honorary lectureship in diagnostics at University College London and Honorary Clinical Scientist roles within the NHS with continued clinical state registration. He is also a member of the Royal College of Pathologists.
Prior to joining Ultromics, Gary led on the innovation of biliary disease products at Perspectum Diagnostics Ltd, playing a key role in FDA clearance and market entry facilitating research and partnering activities.
Gary has also held senior scientific positions within the Healthcare (inc. Oxford University Hospitals) and Pharmaceutical sectors (inc GlaxoSmithKline) where he has brought numerous diagnostic solutions to the market.
Gonzalo is the Chief of Staff at Resolution Therapeutics, and a Partner at Syncona. At Resolution, his responsibilities include day to day management of company operations, hiring, and supporting the scientific team in their delivery of the company plan. Previously, Gonzalo was a Project Leader at The Boston Consulting Group in London, where amongst other responsibilities he advised clients in the biopharmaceuticals and biotechnology industry. Gonzalo holds a degree in Physics and a PhD in Protein Biophysics from the University of Cambridge, including a brief placement in the Department of Cell Biology at Harvard Medical School, and has co-authored 8 peer-reviewed publications published in high-impact interdisciplinary journals such as the Proceedings of the National Academy of Sciences and Nature Communications.
Dr Olivia Rossanese is a cancer biologist and drug discovery professional with experience leading and contributing to discovery and target validation programmes within both academia and the pharmaceutical industry.
She has been involved with the identification of tool molecules, lead compounds, clinical candidates, and two licensed medicines currently in use for the treatment of metastatic melanoma.
She joined The Institute of Cancer Research in 2015 as Head of Biology in the Cancer Research UK Cancer Therapeutics Unit. In March 2020, Dr Rossanese was appointed Interim Head of the Division of Cancer Therapeutics and Interim Director of the Cancer Therapeutics Unit.
Dr Kath Mackay is Managing Director, Bruntwood SciTech - Alderley Park, the UK’s largest single site life science and innovation campus. She is on the leadership team of Bruntwood SciTech - a 50:50 JV between Bruntwood and Legal & General and the UK’s leading property company dedicated to driving to the growth of the science and technology sector.
Kath is also Non-Executive Director of the Northern Health Science Alliance, the Northern Powerhouse for Health helping companies & organisations globally to access the health and life science expertise of 8 cities. Established in 2013 as a partnership between the leading NHS trusts, universities and Academic Health Science Networks across northern England, NHSA combines research and clinical excellence. Kath is also Non Executive Director of Infex Therapeutics, a clinical development company which acquires, develops and licenses innovative drugs to treat pandemic infections, and the National Biofilms Innovation Centre, which is a UKRI funded centre building research and innovation capacity and catalysing collaboration with industry in the study of biofilms to achieve breakthrough innovation.
Kath joined Bruntwood SciTech from Innovate UK where she was Director of Ageing Society, Health and Nutrition, and part of the executive management team leading the economic growth of all industrial sectors through business led innovation. She led the team responsible for growing and scaling businesses working in the biomedical, health, agriculture and food sectors, including development of new challenges under the Government’s Industrial Strategy and responsibility for the Cell & Gene Therapy Catapult and Medicines Discovery Catapult.
Barbara has 30 years’ experience in the life sciences industry. The first 11 years were spent on the commercial side of a large organisation (ICI/Zeneca/AstraZeneca), after which she transitioned to the entrepreneurial world of biotech and emerging companies.
She has worked in a wide range of biotechs, including both therapeutic product and platform technology companies, working in business development, as CEO and in non-exec roles including Chair.
Barbara has been involved in a number of major strategic transactions and fundraising, but her main focus is on helping to build companies. She is Chief Business Officer of Autifony Therapeutics. Barbara is also on the Cambridge Enterprise Seed Investment Committee and chairs the LifeArc Seed Investment Committee.
Katie Binley graduated with a PhD from the University of Sheffield and joined Oxford BioMedica Ltd. As Director of Biology, Katie played a key role in all early-stage proof-of-concept development and clinical translation over a diverse range of therapeutic areas that included several ocular indications (wet age-related macular degeneration, Stargardt Disease and Ushers Syndrome 1B) before project managing a multi-disciplinary team to develop a novel Parkinson’s gene therapy. In 2019, Katie joined the Oxford University spin-out called PepGen as Head of Preclinical Development before joining Ikarovec as the CSO in 2020 to focus on the development of novel gene therapies to treat chronic ophthalmic conditions.
Dr Raine qualified in medicine at Oxford University, and undertook postgraduate research leading to an MSc in pharmacology. After general medical posts, her interest in medicine safety led to a career in medicines regulation. She joined the then Medicines Division of the Department of Health in 1985, moving to the Medicines and Healthcare products Regulatory Agency when it was formed in 2003.
Dr Raine worked in several medicines licensing and post-licensing areas, including medical devices, and became Director of the Agency’s Vigilance and Risk Management of Medicines division in 2006. She was chair of the European Pharmacovigilance Risk Assessment Committee (PRAC) on behalf of the European Medicines Agency from 2012 to 2018.